Savara (SVRA) Total Non-Current Liabilities (2016 - 2026)
Savara (SVRA) posted quarterly Total Non-Current Liabilities of $50.3 million for Q4 2025, up 21.67% year-over-year from $41.3 million in Q4 2024, and up 8.09% quarter-over-quarter from $46.5 million in Q3 2025.
Savara (SVRA) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Savara (SVRA) has reported Total Non-Current Liabilities for 10 consecutive years, with $50.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 21.67% year-over-year to $50.3 million; the TTM figure through Dec 2025 stood at $50.3 million (up 21.67% YoY), while the FY2025 annual figure was $50.3 million, up 21.67% from the prior year.
- Total Non-Current Liabilities advanced to $50.3 million in Q4 2025 per SVRA's latest filing, from $46.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $50.3 million in Q4 2025 and bottomed at $29.6 million in Q1 2022.
- Historically, Total Non-Current Liabilities has averaged $36.1 million across 5 years, with a median of $33.8 million in 2021.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities rose 21.73% — and 2022, when it declined 8.69%.
- Savara's Total Non-Current Liabilities stood at $32.0 million in 2021, then retreated by 0.12% to $31.9 million in 2022, then increased by 15.65% to $36.9 million in 2023, then increased by 11.9% to $41.3 million in 2024, then grew by 21.67% to $50.3 million in 2025.
- Business Quant data shows SVRA's Total Non-Current Liabilities at $50.3 million in Q4 2025, $46.5 million in Q3 2025, and $43.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 47.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.71 Mn |
| Dec 31, 2025 | 50.30 Mn |
| Sep 30, 2025 | 46.54 Mn |
| Jun 30, 2025 | 43.28 Mn |
| Mar 31, 2025 | 41.42 Mn |
| Dec 31, 2024 | 41.34 Mn |
| Sep 30, 2024 | 39.34 Mn |
| Jun 30, 2024 | 37.77 Mn |
| Mar 31, 2024 | 36.23 Mn |
| Dec 31, 2023 | 36.95 Mn |
| Sep 30, 2023 | 35.24 Mn |
| Jun 30, 2023 | 32.10 Mn |
| Mar 31, 2023 | 31.07 Mn |
| Dec 31, 2022 | 31.95 Mn |
| Sep 30, 2022 | 31.17 Mn |
| Jun 30, 2022 | 29.65 Mn |
| Mar 31, 2022 | 29.63 Mn |
| Dec 31, 2021 | 31.98 Mn |
| Sep 30, 2021 | 32.01 Mn |
| Jun 30, 2021 | 31.02 Mn |